Skip to main content

You are here

Erasmus Schneider, Ph.D.

Erasmus Schneider, Ph.D.

Associate Director for Research and Technology
Director of the Scientific Cores
Adjunct Associate Professor, Albany Medical College, Pathology and Laboratory Medicine
Ph.D., University of Bern, Switzerland
Postdoctoral training: University of Auckland
Postdoctoral training: Johns Hopkins University Medical School
Postdoctoral training: National Cancer Institute

Research Interests

Dr. Erasmus Schneider joined the Wadsworth Center in 1995 as a research scientist when he established an externally funded research program to investigate multidrug resistance of cancer cells. This research resulted in numerous peer-reviewed publications and presentations at major conferences. Over the years he has continued to work in the area of cancer cell drug resistance, expanding into drugs targeting the folate pathway and DNA precursor synthesis. He was a grant reviewer for the American Cancer Society and currently is a member of its Council for Extramural Research.

From 2007 to 2013 Dr. Schneider was the director of the Center’s Division of Translational Medicine, and in 2013 assumed his current role as the Center’s Associate Director for Research and Technology. In that role he is, among other things, overseeing the Center’s scientific core facilities and internal research funding programs. In particular, he is guiding the Advanced Genomics Technology Cluster and the Bioinformatics core to provide Next Generation Sequencing for public health investigations and surveillance.

Dr. Schneider is also the section head for Oncology in the Clinical Laboratory Reference System. In that position he is responsible for the review of laboratory developed tests submitted by NYS permitted laboratories in the area of Oncology.

He is particularly interested in the technical and quality control challenges posed by the advanced molecular techniques used for the diagnosis, prognosis and prediction of therapeutic response of cancer.

Select Publications

Yao R, Schneider E.
Detection of B- and T-cell-specific gene rearrangements in 13 cell lines and 50 clinical specimens using the BIOMED-2 and the original InVivoScribe primers.
Leukemia & Lymphoma.
Volk EL, Schneider E.
Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter.
Cancer Research.
Yao R, Rich SA, Schneider E.
Validation of sixteen leukemia and lymphoma cell lines as controls for molecular gene rearrangement assays.
Clinical Chemistry.
Volk, E.L., Farley, K.M., Wu, Y., Li, F., Robey, R.W. and Schneider, E.
Overexpression of wild-type Breast Cancer Resistance Protein mediates methotrexate resistance.
Cancer Res.
Volk, E.L., Rohde, K., Rhee, M., McGuire, J.J., Doyle, L.A., Ross, D.D., and Schneider, E.
Methotrexate cross-resistance in a mitoxantrone selected multidrug-resistant MCF7 breast cancer cell line is due to enhanced energy-dependent drug efflux.
Cancer Res.